Jian Jin
PROFESSOR
Pharmacological Sciences and Oncological Sciences
Icahn School of Medicine at Mount Sinai
United States of America
Biography
Dr. Jian Jin received a B.S. degree in chemistry from University of Science and Technology of China in 1991 and a Ph.D. degree in organic chemistry from the Pennsylvania State University in 1997. After completing a postdoctoral training at the Ohio State University, Dr. Jin joined GlaxoSmithKline as a medicinal chemist in 1998 and had been a manager of medicinal chemistry from 2003 to 2008. In 2008, Dr. Jin joined the Division of Chemical Biology and Medicinal Chemistry at the University of North Carolina at Chapel Hill (UNC – CH) as an Associate Professor. He had also served as an Associate Director of medicinal chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC – CH from 2008 to 2014. In 2014, Dr. Jin was recruited to the Icahn School of Medicine at Mount Sinai (Mount Sinai) as a Professor with Tenure. He is currently a Professor in Department of Pharmacological Sciences and a Professor in Department of Oncological Sciences. Since 2008, Dr. Jin’s laboratory has focused on discovering selective inhibitors of histone methyltransferases and functionally selective ligands of G protein-coupled receptors. To date, Dr. Jin has published more than 100 original research papers and delivered more than 80 invited talks. He is also an inventor of 10 issued U.S. patents and 38 published PCT patent applications.
Research Interest
Cancer, Chromatin, Drug Design and Discovery, Membrane Proteins/Channels, Schizophrenia
Publications
-
Korboukh I, Hull-Ryde EA, Rittiner JE, Randhawa AS, etal (2012) Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice. Journal of medicinal chemistry Vol: 55.
-
Siarheyeva A, Senisterra G, Allali-Hassani A, Dong A, Dobrovetsky E, etal (2012) An allosteric inhibitor of protein arginine methyltransferase 3. Structure Vol: 20.
-
Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, etal (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell Vol: 149.
-
Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, etal (2012) Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature Vol: 481.
-
Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, etal (2011) Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proceedings of the National Academy of Sciences of the United States of America Vol: 108.
-
Liu F, Barsyte-Lovejoy D, Allali-Hassani A, He Y, Herold JM, etal (2011) Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines. Journal of medicinal chemistry Vol: 54.
-
Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, etal (2011) A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature chemical biology Vol: 8.
-
Liu F, Chen X, Allali-Hassani A, Quinn AM, Wigle TJ, etal (2010) Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. Journal of medicinal chemistry Vol: 15.
-
Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, etal (2010) Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. The Journal of clinical investigation Vol: 120.
-
Liu F, Chen X, Allali-Hassani A, Quinn AM, Wasney GA, etal (2009) Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a. Journal of medicinal chemistry Vol: 52.
